Patients and Healthcare Providers to Experience Significant Benefits from the Use of the Internet

The growth of Internet applications in healthcare has been rapid. A growing number of patients are becoming increasingly involved in the healthcare service they receive. These 'power patients' possess characteristics that distinguish them from traditional patients and are an important factor in driving the use of the Internet in healthcare.

"Power patients are a growing share of the population and healthcare organisations will need to meet their needs," notes Frost & Sullivan (http://healthcareIT.frost.com) Industry Analyst Konstantinos Nikolopoulos. "Free choice of doctors, control over treatments received, access to quality information about their care and extremely high levels of customer service are some of the expectations of power patients."

Besides, over the years, healthcare organisations have had to adapt to numerous changes, from advances in diagnostic and therapeutic procedures to the emergence of concepts such as managed care and telemedicine. The e-Health model represents another such change with far-reaching implications for healthcare organisations. In such a scenario, the Internet's capability to empower patients, support information exchange and thus result in new operational strategies, business and service delivery models can be very appealing although quite challenging.

Moreover, public health policies and regulations greatly influence the way in which healthcare organisations can use the Internet. For instance, uncertainty over privacy and security regulations regarding the use of electronic health information can deter organisations from sharing health records or administrative and financial information across the Internet.

"The transition to electronic healthcare and the use of the Internet to exchange health information raises serious security concerns," explains Nikolopoulos. "While the perception of the lack of security is inhibiting the use of the Internet for sharing clinical information, various technologies and procedures are being developed to deal with these security problems."

The European Union is already enforcing strict medical data security standards and the North American market is also demanding improved security and confidentiality in healthcare transactions with the Health Insurance Portability and Accountability Act (HIPAA).

In this scenario, all stakeholders will need to realise that in matters concerning security, privacy and confidentiality, ensuring 100 per cent absolute security and confidentiality is impossible. Instead, maintaining a good balance between actual or realistic needs, risks, costs and potential losses (including the impact on reputation), is essential. Until there is widespread consensus on such issues, security concerns will continue to inhibit the use of the Internet in healthcare.

The Role of the Internet in Healthcare is part of the Healthcare & Life Sciences IT Growth Partnership Service, which also includes research on patient data safety in the European healthcare IT markets, the computerised physician order entry systems market, the electronic medical records market and the hospital information systems market in Europe. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the latest analysis of the Role of the Internet in Healthcare, send an e-mail to Radhika Menon Theodore, Corporate Communications, at This email address is being protected from spambots. You need JavaScript enabled to view it. with your full name, company name, title, telephone number, e-mail address, city, state and country.

About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit http://www.frost.com.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

GSK announces positive Phase IIa study results for…

GSK plc (LSE/NYSE: GSK) announced positive results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well t...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Machine learning can help predict patient response…

Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades. Now, researchers at ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...